Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Eradication of Mycobacterium abscessus infection in cystic fibrosis with initiation of Elexacaftor/Tezacaftor/Ivacaftor
Caoimhe McParland, Matthew Nunn, Theodore K. Marras, et al.
Journal of Cystic Fibrosis (2023) Vol. 23, Iss. 1, pp. 38-40
Closed Access | Times Cited: 14

Showing 14 citing articles:

CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis
Jennifer L. Taylor‐Cousar, Paul D. Robinson, Michal Shteinberg, et al.
The Lancet (2023) Vol. 402, Iss. 10408, pp. 1171-1184
Closed Access | Times Cited: 62
Cystic fibrosis year in review 2024
Amel Alameeri, Burcu Capraz, Francesca Lucca, et al.
Journal of Cystic Fibrosis (2025)
Closed Access | Times Cited: 1
Clinical and radiological improvement of cavitary Mycobacteroides abscessus disease in cystic fibrosis following initiation of elexacaftor/tezacaftor/ivacaftor
Roderick Gavey, J D Nolan, Vanessa Moore, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 5, pp. 1024-1026
Open Access | Times Cited: 5
The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease
Claire Y Mou, Daniel Henderson, Angela Matson, et al.
European Clinical Respiratory Journal (2025) Vol. 12, Iss. 1
Open Access
Nocardia Isolation in People with Cystic Fibrosis and Non-CF Bronchiectasis: A Multicenter Italian Study
Laura Venditto, Daniela Dolce, Silvia Campana, et al.
Antibiotics (2025) Vol. 14, Iss. 3, pp. 317-317
Open Access
Cystic fibrosis year in review 2023
David V. Swetland, Adrienne P. Savant
Pediatric Pulmonology (2024) Vol. 59, Iss. 12, pp. 3106-3116
Open Access | Times Cited: 3
Alternative therapies against Mycobacterium abscessus infections
Ivana Palucci, Giovanni Delogu
Clinical Microbiology and Infection (2023) Vol. 30, Iss. 6, pp. 732-737
Open Access | Times Cited: 9
Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy
Justyna Milczewska, Zulfiya Syunyaeva, Aleksandra Żabińska-Jaroń, et al.
European Respiratory Review (2024) Vol. 33, Iss. 174, pp. 240068-240068
Open Access | Times Cited: 2
Nontuberculous mycobacterial pulmonary infections in the era of elexacaftor-tezacaftor-ivacaftor
Christina M. Mingora, Lindsay J. Caverly
Journal of Cystic Fibrosis (2024) Vol. 23, Iss. 1, pp. 3-4
Closed Access | Times Cited: 1
Antimicrobial and Antibiofilm Effects of Bithionol against Mycobacterium abscessus
Dan Cao, Xin Yuan, Xiuzhi Jiang, et al.
Antibiotics (2024) Vol. 13, Iss. 6, pp. 529-529
Open Access | Times Cited: 1
Mycobacterium abscessus treatment outcomes in cystic fibrosis: A single centre experience
Ieuan Evans, Aaron Weimann, Timothy Baird, et al.
Journal of Cystic Fibrosis (2024)
Open Access | Times Cited: 1
Non-Tuberculous Mycobacterial Infection in Cystic Fibrosis Before and after Initiation of Elexacaftor-Tezacaftor-Ivacaftor: Now is Not the Time to Lower the Guard
Ieuan Evans, Daniel J. Smıth, David W. Reid
(2024)
Closed Access
Linezolid

Reactions Weekly (2024) Vol. 2030, Iss. 1, pp. 261-261
Closed Access
Linezolid

Reactions Weekly (2023) Vol. 1972, Iss. 1, pp. 205-205
Closed Access
Page 1

Scroll to top